Since 2019, three disease-specific therapies have been approved to treat patients with ATTR-CM. The first was Pfizer’s Vyndamax (tafamidis) in May 2019, which was approved for both wild type and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback